| 发明名称 | AGER-peptides and use thereof | ||
| 摘要 | The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER. | ||
| 申请公布号 | US9291621(B2) | 申请公布日期 | 2016.03.22 |
| 申请号 | US200611795282 | 申请日期 | 2006.01.18 |
| 申请人 | AbbVie Deutschland GmbH & Co. KG | 发明人 | Hahn Alfred;Loebbert Ralf;Teusch Nicole;Möller Achim;Ebert Ulrich;Schmidt Martin |
| 分类号 | A61K39/00;G01N33/564;C07K16/28 | 主分类号 | A61K39/00 |
| 代理机构 | Michael Best & Friedrich LLP | 代理人 | Mueller Lisa V.;Michael Best & Friedrich LLP |
| 主权项 | 1. A hybrid protein comprising a) a peptide fragment of the C domain of the receptor for advanced glycation endproducts (AGER-CDP), which is a length of about 30 to about 50 amino acid residues, wherein said AGER-CDP comprises a sequence selected from the group consisting ofDGKPLVPNEKGVSVKEQTRRHPETGLFTLQ,(SEQ ID NO: 31)TLQSELMVTPARGGDPRPTFSCSFSPGLPR,(SEQ ID NO: 32)andLPRHRALRTAPIQPRVWEPVPLEEVQLVVE;(SEQ ID NO: 33)and b) a heterologous protein or protein fragment. | ||
| 地址 | Wiesbaden DE | ||